JP2016530284A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530284A5
JP2016530284A5 JP2016539022A JP2016539022A JP2016530284A5 JP 2016530284 A5 JP2016530284 A5 JP 2016530284A5 JP 2016539022 A JP2016539022 A JP 2016539022A JP 2016539022 A JP2016539022 A JP 2016539022A JP 2016530284 A5 JP2016530284 A5 JP 2016530284A5
Authority
JP
Japan
Prior art keywords
peg
agent
drug
average
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016539022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530284A (ja
JP6509867B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/052638 external-priority patent/WO2015031316A1/en
Publication of JP2016530284A publication Critical patent/JP2016530284A/ja
Publication of JP2016530284A5 publication Critical patent/JP2016530284A5/ja
Application granted granted Critical
Publication of JP6509867B2 publication Critical patent/JP6509867B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016539022A 2013-08-30 2014-08-26 疾患及び障害を治療するためにインターロイキン−10を使用する方法 Expired - Fee Related JP6509867B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361872394P 2013-08-30 2013-08-30
US61/872,394 2013-08-30
PCT/US2014/052638 WO2015031316A1 (en) 2013-08-30 2014-08-26 Methods of using interleukin-10 for treating diseases and disorders

Publications (3)

Publication Number Publication Date
JP2016530284A JP2016530284A (ja) 2016-09-29
JP2016530284A5 true JP2016530284A5 (enExample) 2017-10-05
JP6509867B2 JP6509867B2 (ja) 2019-05-08

Family

ID=52587254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016539022A Expired - Fee Related JP6509867B2 (ja) 2013-08-30 2014-08-26 疾患及び障害を治療するためにインターロイキン−10を使用する方法

Country Status (8)

Country Link
US (2) US10010588B2 (enExample)
EP (1) EP3038642A4 (enExample)
JP (1) JP6509867B2 (enExample)
CN (1) CN105658232A (enExample)
AU (1) AU2014311432A1 (enExample)
CA (1) CA2920679A1 (enExample)
HK (1) HK1226308A1 (enExample)
WO (1) WO2015031316A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP6675394B2 (ja) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−10を使用する方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン10の使用方法
WO2017156128A1 (en) * 2016-03-10 2017-09-14 The Board Of Trustees Of The Leland Stanford Junior University Peptide modulators of specific calcineurin protein-protein interactions
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN121971599A (zh) 2019-02-25 2026-05-05 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
CA3204162A1 (en) 2021-01-11 2022-07-14 Robert Kastelein Compositions and methods related to receptor pairing

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1992012726A1 (en) 1991-01-16 1992-08-06 Schering Corporation Use of interleukin-10 in adoptive immunotherapy of cancer
ES2068705T3 (es) 1991-01-16 1995-04-16 Schering Corp Tratamiento de la enfermedad neoplastica con interleuquina-10.
US5624823A (en) 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994004180A2 (en) 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same
AU6000894A (en) 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5665345A (en) 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
IL110413A0 (en) 1993-07-26 1994-10-21 Schering Corp Agonists and antagonists of human interleukin-10
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PL175343B1 (pl) 1994-01-20 1998-12-31 Schering Corp Sposób pozaustrojowego wytwarzania aktywowanych jednojądrzastych komórek krwi obwodowej, kompozycja farmaceutyczna do pozaustrojowego wytwarzania aktywowanych jednojądrzastych komórek krwi obwodowej i kompozycja farmaceutyczna do leczenia nowotworów
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5866134A (en) 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
US5770190A (en) 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2264918A1 (en) * 1996-09-06 1998-03-12 Schering Corporation Method for lowering cholesterol levels
US5945097A (en) * 1996-09-06 1999-08-31 Schering Corporation Method for lowering cholesterol levels with interleukin-10
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US6685931B1 (en) 1998-12-22 2004-02-03 Schering Corporation Treatment of hepatitis C virus infections with interleukin-10
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
AU5827000A (en) 1999-07-16 2001-02-05 Maria Teresa Bejarano Viral il-10 uses
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
EP1257574A1 (en) 2000-02-11 2002-11-20 Maxygen Aps Improved interleukin 10
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
AU2003280315A1 (en) 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
ES2312820T3 (es) 2002-11-29 2009-03-01 Maria Grazia Roncarolo Paramicina e il-10 para el tratamiento de enfermedades autoinmunes.
AU2003303222A1 (en) 2002-12-19 2004-07-14 Universiteit Gent Mutant proteins showing increased secretion
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
AU2003303636B2 (en) 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EP2284180B1 (en) 2003-03-03 2015-09-09 Dyax Corp. Uses of peptides that specifically bind HGF receptor (cMET)
TW200510454A (en) 2003-04-15 2005-03-16 Smithkline Beecham Corp Conjugates comprising human IL-18 and substitution mutants thereof
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005052159A1 (en) 2003-11-28 2005-06-09 The University Of Sydney Latent phase viral interleukin-10-(vii-10) and uses thereof
AR048035A1 (es) 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
DK1786472T3 (da) 2004-08-10 2013-04-15 Genzyme Corp Antisense-modulering af apolipoprotein B-ekspression
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
GB0500643D0 (en) 2005-01-13 2005-02-23 Renovo Ltd Medicaments
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
US20100028296A1 (en) 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
US7749490B2 (en) 2005-05-31 2010-07-06 The Regents Of The University Of Colorado Mutant IL-10
WO2007003041A1 (en) 2005-07-01 2007-01-11 John Schrader Methods of isolating cells and generating monoclonal antibodies
DK1931704T3 (da) 2005-10-04 2011-03-14 Zymogenetics L L C Frembringelse og rensning af IL-29
US7939056B2 (en) 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
US7868139B2 (en) 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
KR20090027693A (ko) 2006-05-31 2009-03-17 디나벡크 가부시키가이샤 알츠하이머병 치료제
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
US20100068147A1 (en) 2006-10-05 2010-03-18 Agency for Science , Technology and Research Dengue diagnosis and treatment
US8247370B2 (en) 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
AU2008206077A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US8937153B2 (en) 2007-07-31 2015-01-20 Affibody Ab Compositions, methods and uses
WO2009036568A1 (en) 2007-09-19 2009-03-26 University Health Network Methods and compositions for treating tumors and viral infections
US9550827B2 (en) 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
WO2009148915A2 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
WO2010022227A1 (en) 2008-08-20 2010-02-25 Schering Corporation Methods for monitoring il-10 therapy
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
EP3348281B1 (en) 2008-12-17 2023-07-05 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
EP2488553B1 (en) 2009-10-12 2015-06-17 Pfizer Inc. Cancer treatment
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN102711829B (zh) 2009-11-30 2016-03-16 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
AU2011268310A1 (en) 2010-06-16 2013-01-10 Abbvie Inc. Comparison of protein samples
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
NZ604805A (en) 2010-07-09 2014-09-26 Affibody Ab Polypeptides
JP2014502252A (ja) 2010-09-28 2014-01-30 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
GB201018289D0 (en) 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
CN102145178B (zh) 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
WO2013130913A1 (en) 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
WO2014110867A1 (zh) 2013-01-17 2014-07-24 厦门赛诺邦格生物科技有限公司 一种单一官能化的支化聚乙二醇及其修饰的生物相关物质
CN105209054A (zh) * 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CA2908208A1 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
JP2016528879A (ja) * 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160375101A1 (en) 2014-01-15 2016-12-29 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders

Similar Documents

Publication Publication Date Title
RU2015149387A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP2017533201A5 (enExample)
WO2011094337A8 (en) Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
JP2014526441A5 (enExample)
WO2012050923A3 (en) Engineered polypeptides having enhanced duration of action
EA201692466A1 (ru) Жирные кислоты и их применение для конъюгации с биомолекулами
WO2013009545A8 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP2014169326A5 (enExample)
HK1208155A1 (en) Transmucosal delivery of engineered polypeptides
JP2015521607A5 (enExample)
JP2017031213A5 (enExample)
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
NZ593813A (en) Glucagon analogues
JP2016512248A5 (enExample)
HK1205156A1 (en) Cyclodextrin-based polymers for therapeutic delivery
JP2016506727A5 (enExample)
JP2016518351A5 (enExample)
JP2016516076A5 (enExample)
FI3065763T4 (fi) Il-22-dimeerin käyttö lääkkeen valmistamisessa suonensisäistä antoa varten
JP2012517449A5 (enExample)
WO2007059342A3 (en) Random copolymer compositions for treating unwanted immune response
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
WO2021021959A3 (en) Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
JP2016515123A5 (enExample)
JP2016539122A5 (enExample)